K & P FRAMES LIMITED

Financial Health Score: D (Declining Health / Critical Watch)

Explanation: The patient is suffering from chronic equity anemia. While K & P Frames Limited is currently solvent and exhibits no immediate short-term breathing difficulties (liquidity is healthy), the business has suffered a severe, multi-year hemorrhage of shareholder funds. Net assets have plummeted by over 91% in just four years, leaving a dangerously thin financial buffer. The presence of a massive, static provision on the balance sheet acts like an undiagnosed tumor, consuming the company's financial reserves and threatening future viability if not addressed.

Key Vital Signs

1. Net Assets (Shareholders' Funds): £13,203 (Critical) * Interpretation: This is the company's net worth, and it is dangerously low. In 2021, the company had £161,821 in equity. By 2025, this had drained to just £13,203. This represents a 91.8% loss of the company's financial "blood supply" over four years. With share capital at a mere £2, the retained P&L reserve is the only thing keeping the patient alive, and it is rapidly depleting.

2. Current Ratio: 3.27 (Healthy) * Interpretation: Calculated as Current Assets (£148,185) divided by Current Liabilities (£45,288). This indicates that for every £1 of short-term debts, the company has £3.27 in short-term assets. The patient's immediate circulation is fine; there is no risk of cardiac arrest from unpaid suppliers in the near term.

3. Provisions for Liabilities: £79,694 (Severe Risk) * Interpretation: This is a massive figure relative to the size of the company, representing over half of total assets. It has also remained completely static between 2024 and 2025. This acts like a dormant but heavy parasite on the balance sheet—likely a deferred tax provision or a long-term legal/contractual liability. Because it is unchanged year-on-year, it suggests the underlying issue is unresolved and simply accumulating pressure on the company's reserves.

4. Total Assets: £148,185 (Declining) * Interpretation: Total assets have contracted from a peak of £286,285 in 2021 to £148,185 in 2025. Notably, the balance sheet shows zero fixed assets, meaning all assets are current (likely stock, debtors, and cash). The company owns no property or machinery outright, which limits its collateral options if it needs an emergency capital transfusion.

Diagnosis

The financial data reveals a business suffering from Chronic Equity Depletion.

While the company's short-term liquidity (current ratio) presents a false picture of robust health, the underlying condition is deteriorating. The patient is burning through retained earnings year after year. The drop from £161,821 in 2021 to £13,203 in 2025 strongly suggests the company is trading at a loss, with operational revenues insufficient to cover overheads and the stagnant £79,694 provision.

The lack of fixed assets means the business is asset-light, which is not inherently bad, but combined with the shrinking equity base, it means the company has virtually no shock absorbers. If a major customer defaults or an unexpected expense arises, the company's net assets could easily turn negative, pushing it into technical insolvency—a financial cardiac arrest.

Prognosis

Guarded to Poor.

The rate of equity decline is slowing (dropping by only £4,410 in the latest year compared to massive drops in prior years), which is a slight positive. However, the patient is already in a frail state. With net assets of just £13,203 supporting a provision of nearly £80,000, there is a severe structural weakness. If the provision eventually crystallizes into an actual cash outflow, the company will not have the reserves to survive it without external intervention or a significant injection of capital from the directors.

Recommendations

1. Biopsy the Provision: The directors must urgently review the £79,694 provision. Determine exactly when and how this liability will crystalize. If it is a deferred tax liability, plan for its eventual payment. If it is no longer required, release it to the P&L to boost equity.
2. Stop the Bleeding (Restore Profitability): The company needs an operational turnaround. Review pricing strategies, cut unnecessary overheads, and focus on high-margin products to return the P&L to a positive position. The company cannot afford another year of draining its reserves.
3. Capital Transfusion: Given the minimal share capital (£2) and the reliance on retained earnings, the directors (who are also the family shareholders) should consider a capital injection. Paying in additional share capital would thicken the company's financial skin and provide a much-needed buffer against future losses.
4. Monitor Cash Flow Rigorously: While current liquidity is healthy, the shrinking asset base means cash must be managed with strict discipline. Avoid taking on new long-term debts until the existing provision is resolved and profitability is restored.